Biopharma | June 04, 2025
Sanofi exercises license extension option to Nurix’s STAT6 program
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
This program, titled "Food Supplementation and Capacity Building Support for Improved Nutrition in Malinao, Aklan," aligns with the country’s national health
AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
Rad-Sure blood irradiation indicators are FDA 510 (k) cleared medical devices that offer positive visual verification of irradiation at the minimum specified dose
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
Subscribe To Our Newsletter & Stay Updated
